The Hindu Business Line : Ranbaxy to sell products of Daiichi Sankyo in Romania

New Delhi, Sept 2 Terapia S.A., a subsidiary of Ranbaxy in Romania, will start marketing osteoporosis medication — Evista — on behalf of Japanese drug maker Daiichi Sankyo. This is the first time in Europe that Daiichi Sankyo and Ranbaxy are leveraging synergies generated through the hybrid business model.

Commenting on the development, Mr Takashi Shoda, President and Chief Executive Officer of Daiichi Sankyo, said, “We are delighted to announce this latest of the many synergies we will realise through our cooperation with Ranbaxy. We continue to explore other collaborations with Ranbaxy that will help optimise our growth.”

Mr Atul Sobti, Chief Executive Officer and Managing Director of Ranbaxy, said, “The launch of Evista by Terapia Ranbaxy in Romania marks our first international endeavour as a global partnership. Terapia Ranbaxy is a strong player in Europe, and we will provide a unique platform to Daiichi Sankyo for the launch of Evista, and many more new products in the future.”

Acquiring rights

With a population of 22 million people, Romania is Eastern Europe’s second biggest market after Poland. Annual turnover in the Romanian pharmaceutical market totals about $2.5 billion, and the market is growing at around 20 per cent a year, in local currency terms. Established in 1921, Terapia, now Terapia Ranbaxy, is one of the seven largest pharmaceutical companies in Romania.

In 2006, Daiichi Sankyo acquired the marketing and distribution rights for Evista, an osteoporosis treatment, in six European countries from Eli Lilly and Company. In 2008, Daiichi Sankyo acquired additional rights for the drug covering all remaining countries in Europe, with the exception of Greece.

Tamiflu supply

Ranbaxy Laboratories has also received an order from the Indian Government to supply generic version of Roche Holding AG’s Tamiflu, a drug used in the treatment of H1N1 flu.

“Ranbaxy produces Oseltamivir active pharmaceutical ingredient and formulations, and can begin supplies at a fairly short notice,” the Ranbaxy President, Mr Ramesh Adige, said in a statement. The company didn’t disclose further details of the contract. Strides Arcolab Ltd has also received an order from the Government to supply 740,000 doses of Tamiflu.

Related Stories:
Flu drug: Pharma cos asked to report daily stock
Ranbaxy launches new drug for bone disease

More Stories on : New Business | Pharmaceuticals | Ranbaxy Laboratories Ltd

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page